Novel drug-releasing system could aid bladder cancer treatment

Key takeaways:

Most patients with non-muscle-invasive bladder cancer who received TAR-200 with gemcitabine achieved complete response.

Multiple patients have had responses persist for more than 2 years.

A novel drug-releasing system for bladder cancer that allows for sustained delivery of medicine for several weeks recently received FDA approval after producing superior and longer-lasting response results than historical standards.

Data from a phase 2b study showed more than 80% of patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer who received TAR-200, a small drug releasing system placed in the bladder that delivered gemcitabine over a 3-week period, had a complete response to treatment.

Data derived from Daneshmand S, et al. J